Chronic Total Occlusion of Coronary ArteryPETS-CTONCT04145167
Observational Registry on Clinical Outcome After Diagnosis of Chronic Total Occlusions
An observational study of Chronic Total Occlusion of Coronary Artery and Angina Pectoris, run by Ziekenhuis Netwerk Antwerpen (ZNA) at 1 site in Belgium.
Trial summary
This registry aims at enrolling all consecutive patients presenting with at least one chronic total occlusion at coronary angiogram as diagnosed during angiography in our catheterization laboratory during 1 year. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Chronic Total Occlusion of Coronary Artery, Angina Pectoris
- How many people
- 400 participants
- Where
- 1 siteBelgium
- Study dates
- 10 Oct 2019to Dec 2022
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population includes all patients aged >18 with coronary artery disease undergoing coronary catheterization. Key condition to be enrolled in the registry is the evidence of chronic total occlusion and the will to participate in the study.
Who may be able to join
- Presence of at least one untreated CTO at basal angiography (defined as a total occlusion in any major coronary vessel or relevant side branches [reference vessel diameter ≥2.5mm or as judged by two independent interventional cardiologists], with TIMI 0 in the distal segment and at least 3 months old - according to clinical information or of unknown age).
- In patients with history of CABG, a CTO can be included when the occlusion is located in a vessel without a graft in the distal vessel or in case of graft occlusion.
- Age > 18 years
- Willing to participate and able to understand, read and sign the informed consent document after the diagnostic procedure
Who cannot join
- Lack of will to participate in the study or inability to provide informed consent (e.g. by patient admitted with cardiac arrest or unconscious)
Trial locations and contacts
1 site in 1 country.
Belgium1 site, 1 recruiting
- Recruiting
ZNA Middelheim
Antwerp, 2020
Pierfrancesco Agostoni, MD PhD, 0032495637041 ext. 0032495637041, agostonipf@gmail.com
Pierfrancesco Agostoni, MD PhD
About this study
Official title: Prospective Evaluation of Treatment Strategies in Patients Presenting With Chronic Total Occlusions at Coronary Angiogram
This registry aims at enrolling all consecutive patients presenting with at least one chronic total occlusion at coronary angiogram as diagnosed during angiography in our catheterization laboratory during 1 year.
All patients will undergo - whenever possible - a cardiopulmonary excercise test and a non-invasive investigation for myocardial ischemia/viability (by means of echo-dobutamine stress test or perfusion scintigraphy or cardiac magnetic resonance) prior to any eventual revascularization therapy. All patients - including those treated by medical therapy only - will repeat the same investigations after one year of follow-up. In addition to these investigations, clinical outcome and quality of life (including the Seattle Angina Questionnarie and a dedicated depression questionnaire) will be evaluated at baseline and at follow-up.
Primary objective of this study is to investigate the improvement in physical conditions (as expressed by the performance at follow-up CP test), the reduction in ischemia (as evaluated by follow-up non-invasive imaging tests) and the severity of angina according to clinical assessment (including Seattle Angina Questionnaires [SAQ], Canadian Class Score[CCS] and 6-mins walking test).
Read the detailed description
Background The clinical benefits of performing chronic total occlusion (CTO) percutaneous coronary intervention (PCI) represent still a matter of debate in the community of interventional cardiologists[1]. Improvements in terms of symptoms' relief after successful CTO recanalization are growing, with emerging data from randomized clinical trials (RCT) [2] in addition to the already existing large registries[3,4]. In addition, these registries offer data supporting reduction in hard clinical endpoints - including incidence of myocardial infarction (MI) and cardiac death - which however, has so far not been confirmed in RCT. Furthermore, data regarding reduction in ischemia burden after successful CTO-PCI - despite intuitive - and its clinical implications are still lacking, with only a small registry[5] reporting on improved Cardiopulmonary Exercise parameters after successful CTO recanalization. It's also widely known that chronic (refractory) angina significantly impacts the daily life of patients with CTO lesions, not only affecting their quality of life, but also leading to a de-conditioning and a self-limitation in daily activities, creating a negative loop that further reduce the efforts tolerance in these delicate patients. Moreover, recent data suggest that incidence of depression is common among patients with known coronary CTO, and that benefits from successful CTO-PCI may include improvements in psychological health[6].
Of note, the outcome of patients presenting with CTO lesions has been so far investigated only in selected groups of populations (including those with evidence of ischemia/viability, those undergoing CTO-PCI procedures…). However, a systematic and prospective analysis of all consecutive patients presenting with CTO lesions during coronary angiogram, independently by any therapeutic strategy, is so far lacking.
Objective Aim of this registry is to include all consecutive patients presenting with CTO lesion in a relevant coronary vessel (or relevant side branch [namely any coronary vessel with diameter ≥2.5mm]) during cardiac catheterization, to comprehensively analyse their characteristics and to investigate the clinical outcome at 1 year, independently of their therapeutic work-up.
Methodology All patients undergoing coronary angiogram in our centre will be screened for eligibility in the registry. Inclusion and exclusion criteria are here reported.
Inclusion Criteria:
- Presence of at least one untreated CTO at basal angiography (defined as a total occlusion in any major coronary vessel or relevant side branches [reference vessel diameter ≥2.5mm or as judged by two independent interventional cardiologists], with TIMI 0 in the distal segment and at least 3 months old - according to clinical information or of unknown age).
- In patients with history of CABG, a CTO can be included when the occlusion is located in a vessel without a graft in the distal vessel or in case of graft occlusion.
- Age > 18 years
- Willing to participate and able to understand, read and sign the informed consent document after the diagnostic procedure
By study design, no specific exclusion criteria are indicated, except for the lack of will to participate in the study or inability to provide informed consent (e.g. by patient admitted with cardia arrest or unconscious).
Written informed consent form will be collected in all patients.
Withdrawal criteria Patients will be able to withdraw from the study at any time at their request.
Briefly, all patients fulfilling the inclusion criteria will be enrolled in this registry. Of note, the relevance of the CTO-vessel will be adjudicated by two different experienced interventional cardiologists. CTO of small vessels without haemodynamic relevance will not be included in this study. After evaluation in a dedicated CTO-outpatient clinic, they will undergo a cardiopulmonary exercise test (Baseline CP test) and MIBI-scan before any therapeutic strategy (including CTO-PCI or surgical revascularization).
After one year from the enrolment, patients will be evaluated again in the dedicated outpatient clinic, with repeated imaging and functional tests.
Study Objective Primary objective of this study is the improvement in physical conditions as expressed by the performance at follow-up CP test, the reduction in ischemia as evaluated by follow-up MIBI-scan and the severity of angina according to clinical assessment (including Seattle Angina Questionnaires [SAQ], Canadian Class Score[CCS] and 6-mins walking test). Quality of life will also be assessed by means of a dedicated Depression score. These outcomes will be stratified according to the therapeutic strategy adopted in each patient (namely optimal medical treatment alone, CTO-PCI or surgical revascularization).
Secondary endpoints will include a composite of major adverse clinical events (defined as cardiovascular death, myocardial infarction and ischemia-driven revascularization), re-hospitalization for angina/heart-failure, bleeding episodes, strokes and need for specialist/non-specialist outpatient evaluation because angina in the study period.
Sample Sizing By study design, all consecutive patients presenting with relevant CTO lesions at coronary angiogram will be included in the analysis. Given the explorative nature of this registry (at present no similar studies are available in the literature), a solid sample-sizing cannot be performed.
Considering the reported incidence of CTO lesions - ranging from 15-25% of the coronary angiographies performed - and the procedure-volume of this centre (approximately 4000 coronary angiograms per year), a 1-year of consecutive enrolment should provide a large number of subjects (approximately 600) to investigate with solidity eventual significant improvements in the primary endpoints.
Previous registries have reported on the outcome of CTO-PCI procedures in terms of CPET parameters, enrolling approximately 30 patients [7], however given the purely observational nature of this study and the fact the many patients could result not eligible to perform an exercise test (similarly for the echo-stress investigation), a large patient pool has been selected for the present registry, in order to provide solid data for this analysis and a possibly clear response to this unresolved clinical controversy.
Duration of the study (per patient) The duration of participation for each patient will be approximately 1 year. Patients presenting with evidence of CTO lesions at angiography will be screened and, if meeting the study eligibility criteria, will be enrolled in the study. A comprehensive clinical evaluation, together with cardiopulmonary exercise test and MIBI-scan will be performed in the month following the enrollment. Independently of the subsequent treatment strategies, patients will be followed-up for 1 year, including a new clinical evaluation in outpatient setting with cardiopulmonary test and MIBI-scan at the end of the follow-up.
- Keywords
- chronic total occlusion, coronary percutaneous intervention, ischemic heart disease
- Medical subject headings
- Angina Pectoris, Myocardial Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Medical Treatment | This group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by medical therapy only, for any clinical/angiographic/instrumental indication. | |
| Percutaneous intervention | This group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by percutaneous intervention (CTO-PCI), as indicated by the heart-team. | |
| Surgical treatment | This group will include all patients with a diagnose of coronary chronic total occlusions (generally not isolated) who will be treated by means of coronary artery by-pass grafting (CABG), as indicated by heart-team decision. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction in ischemia and angina paramteres
Parameters of Cardiopulmonary Exercise test, non-invasive imaging tests and angina questionnaires.
Measured: 1 year
Secondary outcomes (3)
Composite of major adverse clinical events
Composite of cardiac death, myocardial infarction and ischemia-driven revascularization.
Measured: 1 year
Re-hospitalization
Episodes of re-hospitalization due to angina/heart-failure
Measured: 1 year
Outpatient clinic evaluation
Need for specialist/non-specialist outpatient evaluation because angina
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2019
- Study start10 Oct 2019
- Primary completionDec 2021 (estimated)
- Study completionDec 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Chronic Total Occlusion of Coronary ArteryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Ziekenhuis Netwerk Antwerpen (ZNA)
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Pierfrancesco Agostoni, Ziekenhuis Netwerk Antwerpen (ZNA)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04145167
- Sponsor's protocol ID
- EC 5269
- Acronym
- PETS-CTO
- Status last verified
- Jul 2021
- First submitted
- 28 Oct 2019
- Last updated
- 15 Jul 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Tajti P, Brilakis ES. Chronic Total Occlusion Percutaneous Coronary Intervention: Evidence and Controversies. J Am Heart Assoc. 2018 Jan 12;7(2):e006732. doi: 10.1161/JAHA.117.006732. No abstract available.
PubMed 29330258Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, Rumoroso JR, Erglis A, Christiansen EH, Escaned J, di Mario C, Hovasse T, Teruel L, Bufe A, Lauer B, Bogaerts K, Goicolea J, Spratt JC, Gershlick AH, Galassi AR, Louvard Y; EUROCTO trial investigators. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018 Jul 7;39(26):2484-2493. doi: 10.1093/eurheartj/ehy220.
PubMed 29722796Tomasello SD, Boukhris M, Giubilato S, Marza F, Garbo R, Contegiacomo G, Marzocchi A, Niccoli G, Gagnor A, Varbella F, Desideri A, Rubartelli P, Cioppa A, Baralis G, Galassi AR. Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. Eur Heart J. 2015 Dec 1;36(45):3189-98. doi: 10.1093/eurheartj/ehv450. Epub 2015 Sep 2.
PubMed 26333367Jang WJ, Yang JH, Choi SH, Song YB, Hahn JY, Choi JH, Kim WS, Lee YT, Gwon HC. Long-term survival benefit of revascularization compared with medical therapy in patients with coronary chronic total occlusion and well-developed collateral circulation. JACC Cardiovasc Interv. 2015 Feb;8(2):271-279. doi: 10.1016/j.jcin.2014.10.010.
PubMed 25700750Abdullah SM, Hastings JL, Amsavelu S, Garcia-Morales F, Hendrix F, Karatasakis A, Danek BA, Karacsonyi J, Rangan BV, Roesle M, Khalili H, Banerjee S, Brilakis ES. Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions Improves Peak Oxygen Uptake During Cardiopulmonary Exercise Testing. J Invasive Cardiol. 2017 Mar;29(3):83-91.
PubMed 28255103Yeh RW, Tamez H, Secemsky EA, Grantham JA, Sapontis J, Spertus JA, Cohen DJ, Nicholson WJ, Gosch K, Jones PG, Valsdottir LR, Bruckel J, Lombardi WL, Jaffer FA. Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention: The OPEN-CTO Registry. JACC Cardiovasc Interv. 2019 Apr 8;12(7):651-658. doi: 10.1016/j.jcin.2018.12.029. Epub 2019 Mar 13.
PubMed 30878475Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449. No abstract available.
PubMed 21670242Poletti E, Zivelonghi C, Castaldi G, Vermeersch P, Convens C, Selleslagh P, Prihadi E, Droogmans S, Scott B, Agostoni P. Prospective Evaluation of Treatment Strategies in Patients Presenting With Chronic Total Occlusion: The PETS-CTO Registry. Catheter Cardiovasc Interv. 2025 Jul;106(1):443-453. doi: 10.1002/ccd.31559. Epub 2025 Apr 28.
PubMed 40296468
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Evaluation of Treatment Strategies in Patients Presenting With Chronic Total Occlusions at Coronary Angiogram
- ClinicalTrials.gov ID
- NCT04145167
- Acronym / sponsor ID
- PETS-CTO / EC 5269
- Keywords
- chronic total occlusion, coronary percutaneous intervention, ischemic heart disease
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Ziekenhuis Netwerk Antwerpen (ZNA)University, hospital or other
- Study start
- 10 Oct 2019 (actual)
- Primary completion
- Dec 2021 (estimated)
- Study completion
- Dec 2022 (estimated)
- First posted
- 30 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This registry aims at enrolling all consecutive patients presenting with at least one chronic total occlusion at coronary angiogram as diagnosed during angiography in our catheterization laboratory during 1 year.
All patients will undergo - whenever possible - a cardiopulmonary excercise test and a non-invasive investigation for myocardial ischemia/viability (by means of echo-dobutamine stress test or perfusion scintigraphy or cardiac magnetic resonance) prior to any eventual revascularization therapy. All patients - including those treated by medical therapy only - will repeat the same investigations after one year of follow-up. In addition to these investigations, clinical outcome and quality of life (including the Seattle Angina Questionnarie and a dedicated depression questionnaire) will be evaluated at baseline and at follow-up.
Primary objective of this study is to investigate the improvement in physical conditions (as expressed by the performance at follow-up CP test), the reduction in ischemia (as evaluated by follow-up non-invasive imaging tests) and the severity of angina according to clinical assessment (including Seattle Angina Questionnaires [SAQ], Canadian Class Score[CCS] and 6-mins walking test).
Detailed description
Background The clinical benefits of performing chronic total occlusion (CTO) percutaneous coronary intervention (PCI) represent still a matter of debate in the community of interventional cardiologists[1]. Improvements in terms of symptoms' relief after successful CTO recanalization are growing, with emerging data from randomized clinical trials (RCT) [2] in addition to the already existing large registries[3,4]. In addition, these registries offer data supporting reduction in hard clinical endpoints - including incidence of myocardial infarction (MI) and cardiac death - which however, has so far not been confirmed in RCT. Furthermore, data regarding reduction in ischemia burden after successful CTO-PCI - despite intuitive - and its clinical implications are still lacking, with only a small registry[5] reporting on improved Cardiopulmonary Exercise parameters after successful CTO recanalization. It's also widely known that chronic (refractory) angina significantly impacts the daily life of patients with CTO lesions, not only affecting their quality of life, but also leading to a de-conditioning and a self-limitation in daily activities, creating a negative loop that further reduce the efforts tolerance in these delicate patients. Moreover, recent data suggest that incidence of depression is common among patients with known coronary CTO, and that benefits from successful CTO-PCI may include improvements in psychological health[6].
Of note, the outcome of patients presenting with CTO lesions has been so far investigated only in selected groups of populations (including those with evidence of ischemia/viability, those undergoing CTO-PCI procedures…). However, a systematic and prospective analysis of all consecutive patients presenting with CTO lesions during coronary angiogram, independently by any therapeutic strategy, is so far lacking.
Objective Aim of this registry is to include all consecutive patients presenting with CTO lesion in a relevant coronary vessel (or relevant side branch [namely any coronary vessel with diameter ≥2.5mm]) during cardiac catheterization, to comprehensively analyse their characteristics and to investigate the clinical outcome at 1 year, independently of their therapeutic work-up.
Methodology All patients undergoing coronary angiogram in our centre will be screened for eligibility in the registry. Inclusion and exclusion criteria are here reported.
Inclusion Criteria:
- Presence of at least one untreated CTO at basal angiography (defined as a total occlusion in any major coronary vessel or relevant side branches [reference vessel diameter ≥2.5mm or as judged by two independent interventional cardiologists], with TIMI 0 in the distal segment and at least 3 months old - according to clinical information or of unknown age).
- In patients with history of CABG, a CTO can be included when the occlusion is located in a vessel without a graft in the distal vessel or in case of graft occlusion.
- Age > 18 years
- Willing to participate and able to understand, read and sign the informed consent document after the diagnostic procedure
By study design, no specific exclusion criteria are indicated, except for the lack of will to participate in the study or inability to provide informed consent (e.g. by patient admitted with cardia arrest or unconscious).
Written informed consent form will be collected in all patients.
Withdrawal criteria Patients will be able to withdraw from the study at any time at their request.
Briefly, all patients fulfilling the inclusion criteria will be enrolled in this registry. Of note, the relevance of the CTO-vessel will be adjudicated by two different experienced interventional cardiologists. CTO of small vessels without haemodynamic relevance will not be included in this study. After evaluation in a dedicated CTO-outpatient clinic, they will undergo a cardiopulmonary exercise test (Baseline CP test) and MIBI-scan before any therapeutic strategy (including CTO-PCI or surgical revascularization).
After one year from the enrolment, patients will be evaluated again in the dedicated outpatient clinic, with repeated imaging and functional tests.
Study Objective Primary objective of this study is the improvement in physical conditions as expressed by the performance at follow-up CP test, the reduction in ischemia as evaluated by follow-up MIBI-scan and the severity of angina according to clinical assessment (including Seattle Angina Questionnaires [SAQ], Canadian Class Score[CCS] and 6-mins walking test). Quality of life will also be assessed by means of a dedicated Depression score. These outcomes will be stratified according to the therapeutic strategy adopted in each patient (namely optimal medical treatment alone, CTO-PCI or surgical revascularization).
Secondary endpoints will include a composite of major adverse clinical events (defined as cardiovascular death, myocardial infarction and ischemia-driven revascularization), re-hospitalization for angina/heart-failure, bleeding episodes, strokes and need for specialist/non-specialist outpatient evaluation because angina in the study period.
Sample Sizing By study design, all consecutive patients presenting with relevant CTO lesions at coronary angiogram will be included in the analysis. Given the explorative nature of this registry (at present no similar studies are available in the literature), a solid sample-sizing cannot be performed.
Considering the reported incidence of CTO lesions - ranging from 15-25% of the coronary angiographies performed - and the procedure-volume of this centre (approximately 4000 coronary angiograms per year), a 1-year of consecutive enrolment should provide a large number of subjects (approximately 600) to investigate with solidity eventual significant improvements in the primary endpoints.
Previous registries have reported on the outcome of CTO-PCI procedures in terms of CPET parameters, enrolling approximately 30 patients [7], however given the purely observational nature of this study and the fact the many patients could result not eligible to perform an exercise test (similarly for the echo-stress investigation), a large patient pool has been selected for the present registry, in order to provide solid data for this analysis and a possibly clear response to this unresolved clinical controversy.
Duration of the study (per patient) The duration of participation for each patient will be approximately 1 year. Patients presenting with evidence of CTO lesions at angiography will be screened and, if meeting the study eligibility criteria, will be enrolled in the study. A comprehensive clinical evaluation, together with cardiopulmonary exercise test and MIBI-scan will be performed in the month following the enrollment. Independently of the subsequent treatment strategies, patients will be followed-up for 1 year, including a new clinical evaluation in outpatient setting with cardiopulmonary test and MIBI-scan at the end of the follow-up.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Medical Treatment | – | –This group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by medical therapy only, for any clinical/angiographic/instrumental indication. |
| Percutaneous intervention | – | –This group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by percutaneous intervention (CTO-PCI), as indicated by the heart-team. |
| Surgical treatment | – | –This group will include all patients with a diagnose of coronary chronic total occlusions (generally not isolated) who will be treated by means of coronary artery by-pass grafting (CABG), as indicated by heart-team decision. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population includes all patients aged >18 with coronary artery disease undergoing coronary catheterization. Key condition to be enrolled in the registry is the evidence of chronic total occlusion and the will to participate in the study.
Key inclusion criteria (4 listed)
- Presence of at least one untreated CTO at basal angiography (defined as a total occlusion in any major coronary vessel or relevant side branches [reference vessel diameter ≥2.5mm or as judged by two independent interventional cardiologists], with TIMI 0 in the distal segment and at least 3 months old - according to clinical information or of unknown age).
- In patients with history of CABG, a CTO can be included when the occlusion is located in a vessel without a graft in the distal vessel or in case of graft occlusion.
- Age > 18 years
- Willing to participate and able to understand, read and sign the informed consent document after the diagnostic procedure
Key exclusion criteria (1 listed)
- Lack of will to participate in the study or inability to provide informed consent (e.g. by patient admitted with cardiac arrest or unconscious)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Reduction in ischemia and angina paramteres
Time frame: 1 year
Parameters of Cardiopulmonary Exercise test, non-invasive imaging tests and angina questionnaires.
3 secondary outcomes
Composite of major adverse clinical events
Time frame: 1 year
Re-hospitalization
Time frame: 1 year
Outpatient clinic evaluation
Time frame: 1 year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2021.
- Background: PubMed 29330258Tajti P, Brilakis ES. Chronic Total Occlusion Percutaneous Coronary Intervention: Evidence and Controversies. J Am Heart Assoc. 2018 Jan 12;7(2):e006732. doi: 10.1161/JAHA.117.006732. No abstract available.
- Background: PubMed 29722796Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, Rumoroso JR, Erglis A, Christiansen EH, Escaned J, di Mario C, Hovasse T, Teruel L, Bufe A, Lauer B, Bogaerts K, Goicolea J, Spratt JC, Gershlick AH, Galassi AR, Louvard Y; EUROCTO trial investigators. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018 Jul 7;39(26):2484-2493. doi: 10.1093/eurheartj/ehy220.
- Background: PubMed 26333367Tomasello SD, Boukhris M, Giubilato S, Marza F, Garbo R, Contegiacomo G, Marzocchi A, Niccoli G, Gagnor A, Varbella F, Desideri A, Rubartelli P, Cioppa A, Baralis G, Galassi AR. Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. Eur Heart J. 2015 Dec 1;36(45):3189-98. doi: 10.1093/eurheartj/ehv450. Epub 2015 Sep 2.
- Background: PubMed 25700750Jang WJ, Yang JH, Choi SH, Song YB, Hahn JY, Choi JH, Kim WS, Lee YT, Gwon HC. Long-term survival benefit of revascularization compared with medical therapy in patients with coronary chronic total occlusion and well-developed collateral circulation. JACC Cardiovasc Interv. 2015 Feb;8(2):271-279. doi: 10.1016/j.jcin.2014.10.010.
- Background: PubMed 28255103Abdullah SM, Hastings JL, Amsavelu S, Garcia-Morales F, Hendrix F, Karatasakis A, Danek BA, Karacsonyi J, Rangan BV, Roesle M, Khalili H, Banerjee S, Brilakis ES. Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions Improves Peak Oxygen Uptake During Cardiopulmonary Exercise Testing. J Invasive Cardiol. 2017 Mar;29(3):83-91.
- Background: PubMed 30878475Yeh RW, Tamez H, Secemsky EA, Grantham JA, Sapontis J, Spertus JA, Cohen DJ, Nicholson WJ, Gosch K, Jones PG, Valsdottir LR, Bruckel J, Lombardi WL, Jaffer FA. Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention: The OPEN-CTO Registry. JACC Cardiovasc Interv. 2019 Apr 8;12(7):651-658. doi: 10.1016/j.jcin.2018.12.029. Epub 2019 Mar 13.
- Background: PubMed 21670242Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449. No abstract available.
- Derived from this study: PubMed 40296468Poletti E, Zivelonghi C, Castaldi G, Vermeersch P, Convens C, Selleslagh P, Prihadi E, Droogmans S, Scott B, Agostoni P. Prospective Evaluation of Treatment Strategies in Patients Presenting With Chronic Total Occlusion: The PETS-CTO Registry. Catheter Cardiovasc Interv. 2025 Jul;106(1):443-453. doi: 10.1002/ccd.31559. Epub 2025 Apr 28.
- Individual participant dataSharing planned: Undecided
Related trials for Chronic Total Occlusion of Coronary Artery
Active, not recruiting
To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.
Chronic Total Occlusion of Coronary Artery
RecruitingObservational study
Real-World Outcomes of Drug-Coated Balloon Angioplasty in Coronary Artery Disease
Coronary Artery Disease
RecruitingObservational study
Predicting Functional Recovery After Coronary Chronic Total Occlusion Revascularization
Chronic Total Occlusions of Coronary Arteries, Stress Echocardiography (SE)
Not yet recruiting
Drug-Coated Balloon Only Strategy After Recanalization of Chronic Total Coronary Occlusions
Angina (Stable), Coronary Occlusion
RecruitingObservational study
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Total Occlusion of Coronary Artery and Angina Pectoris, run by Ziekenhuis Netwerk Antwerpen (ZNA) at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Pierfrancesco Agostoni, MD PhD (0032495637041, agostonipf@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction in ischemia and angina paramteres (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04145167, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2021.